Cue Biopharma, Inc. (CUE) Hit All-Time High

March 14, 2018 - By Maria Brooks

The stock of Cue Biopharma, Inc. (NASDAQ:CUE) reached all time high today, Mar, 14 and still has $17.93 target or 4.00 % above today’s $17.25 share price. This indicates more upside for the $335.53M company. This technical setup was reported by If the $17.93 PT is reached, the company will be worth $13.42 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 1.38% or $0.235 during the last trading session, reaching $17.245. About 101,972 shares traded or 20.21% up from the average. Cue Biopharma, Inc. (NASDAQ:CUE) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

More notable recent Cue Biopharma, Inc. (NASDAQ:CUE) news were published by: which released: “Cue Biopharma to Provide Corporate Update at the 10th Annual Biotech Showcase …” on January 04, 2018, also with their article: “Cue Biopharma Announces Appointment of Colin Sandercock as Senior Vice …” published on December 05, 2017, published: “Cue Biopharma Proposes $60 Million IPO Terms” on December 18, 2017. More interesting news about Cue Biopharma, Inc. (NASDAQ:CUE) were released by: and their article: “Cue Biopharma Announces Strategic Research Collaboration and License Agreement …” published on November 16, 2017 as well as‘s news article titled: “Cue Biopharma Appoints Mary Simcox, Ph.D. as Vice President of Translational …” with publication date: July 25, 2017.

Cue Biopharma, Inc., a preclinical stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat various cancers and autoimmune disorders. The company has market cap of $335.53 million. The Company’s lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. It currently has negative earnings. The company's biologics drug candidates also include CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: